TY  -  
T1  - DNA methylation signature (SAM40) identifies subgroups of the Luminal A breast cancer samples with distinct survival 
SN  -  /  
UR  - http://hdl.handle.net/10138/174563 
T3  -  
A1  - Fleischer, Thomas; Klajic, Jovana; Aure, Miriam Ragle; Louhimo, Riku; Pladsen, Arne V.; Ottestad, Lars; Touleimat, Nizar; Laakso, Marko; Halvorsen, Ann Rita; Alnaes, Grethe I. Grenaker; Riis, Margit L. H.; Helland, Aslaug; Hautaniemi, Sampsa; Lonning, Per Eystein; Naume, Bjorn; Borresen-Dale, Anne-Lise; Tost, Joerg; Kristensen, Vessela N. 
A2  -  
PB  -  
Y1  - 2017 
LA  - eng 
AB  - Breast cancer patients with Luminal A disease generally have a good prognosis, but among this patient group are patients with good prognosis that are currently overtreated with adjuvant chemotherapy, and also patients that have a bad prognosis and should be given more aggressive treatment. There is no available method for subclassification of this patient group. Here we present a DNA methylation signature (SAM40) that segregates Luminal A patients based on prognosis, and identify one good progno... 
VO  -  
IS  -  
SP  -  
OP  -  
KW  - breast cancer; Luminal A; DNA methylation; classification; prognosis; GENE-EXPRESSION PROFILES; MOLECULAR SUBTYPES; TUMORS; RISK; NORMALIZATION; DOXORUBICIN; RECURRENCE; PROGNOSIS; PATTERNS; DENSITY; 3122 Cancers; 1182 Biochemistry, cell and molecular biology 
N1  -   
PP  -  
ER  -